(BIM) Biomerieux - Ratings and Ratios
Diagnostic, Instruments, Reagents, Software, Services
Dividends
| Dividend Yield | 0.83% |
| Yield on Cost 5y | 0.77% |
| Yield CAGR 5y | 45.43% |
| Payout Consistency | 92.6% |
| Payout Ratio | 28.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 20.8% |
| Value at Risk 5%th | 32.2% |
| Relative Tail Risk | -5.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | 3.27 |
| CAGR/Max DD | 0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.315 |
| Beta | 0.026 |
| Beta Downside | 0.143 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.78% |
| Mean DD | 6.06% |
| Median DD | 5.36% |
Description: BIM Biomerieux October 30, 2025
bioMérieux S.A. (ticker BIM, France) is a global in-vitro diagnostic (IVD) company headquartered in Marcy-l’Étoile, France. Founded in 1963 and now a subsidiary of Institut Mérieux SA, it serves hospitals, clinical labs, and public-health agencies across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific.
The firm’s product suite spans culture media (CHROMID), rapid biochemical tests (RAPIDEC CARBA NP), automated blood-culture systems (BACT/ALERT VIRTUO/3D), multiplex PCR platforms (BIOFIRE, BIOFIRE SPOTFIRE), mass-spectrometry identification (VITEK MS), automated susceptibility testing (VITEK 2, VITEK REVEAL, ETEST), whole-genome sequencing (EPISEQ CS), and point-of-care immuno-assays (VIDAS). Complementary software (bioMérieux Vision Suite) and sample-prep technologies (NUCLISENS, EMAG) round out its end-to-end diagnostics offering.
Key financial and sector metrics (as of FY 2023) include €3.2 billion in revenue, a 12 % operating margin, and R&D spending of roughly 9 % of sales-both above the average for the GICS Biotechnology sub-industry. The IVD market is projected to grow at a 6-7 % CAGR through 2030, driven by rising antimicrobial-resistance concerns, expanding molecular-diagnostic adoption, and sustained demand for rapid sepsis testing-trends that directly benefit bioMérieux’s product pipeline. The company’s partnership network (e.g., Boehringer Ingelheim, Evotec) and its pipeline of FDA-cleared assays provide additional upside, though execution risk remains around regulatory timelines and competitive pricing pressure.
For a data-rich, objective view of how bioMérieux’s valuation compares to peers and the broader IVD landscape, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income (660.4m TTM) > 0 and > 6% of Revenue (6% = 408.5m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 8.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.68% (prev 19.94%; Δ -1.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.24 (>3.0%) and CFO 1.28b > Net Income 660.4m (YES >=105%, WARN >=100%) |
| Net Debt (125.9m) to EBITDA (1.53b) ratio: 0.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (118.9m) change vs 12m ago -0.04% (target <= -2.0% for YES) |
| Gross Margin 54.80% (prev 51.83%; Δ 2.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 128.2% (prev 106.6%; Δ 21.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 40.01 (EBITDA TTM 1.53b / Interest Expense TTM 25.9m) >= 6 (WARN >= 3) |
Altman Z'' 2.93
| (A) 0.24 = (Total Current Assets 2.28b - Total Current Liabilities 1.00b) / Total Assets 5.37b |
| (B) 0.03 = Retained Earnings (Balance) 161.0m / Total Assets 5.37b |
| (C) 0.19 = EBIT TTM 1.03b / Avg Total Assets 5.31b |
| (D) -0.03 = Book Value of Equity -48.6m / Total Liabilities 1.43b |
| Total Rating: 2.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.16
| 1. Piotroski 9.50pt |
| 2. FCF Yield 4.78% |
| 3. FCF Margin 8.75% |
| 4. Debt/Equity 0.13 |
| 5. Debt/Ebitda 0.08 |
| 6. ROIC - WACC (= 12.41)% |
| 7. RoE 16.76% |
| 8. Rev. Trend 9.02% |
| 9. EPS Trend -9.53% |
What is the price of BIM shares?
Over the past week, the price has changed by +1.88%, over one month by +2.26%, over three months by -4.74% and over the past year by +7.06%.
Is BIM a buy, sell or hold?
What are the forecasts/targets for the BIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 123.5 | 13.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 105.7 | -2.6% |
BIM Fundamental Data Overview December 12, 2025
Market Cap EUR = 12.34b (12.34b EUR * 1.0 EUR.EUR)
P/E Trailing = 32.9653
P/E Forward = 21.7865
P/S = 2.9934
P/B = 3.1333
P/EG = 1.7418
Beta = 0.652
Revenue TTM = 6.81b EUR
EBIT TTM = 1.03b EUR
EBITDA TTM = 1.53b EUR
Long Term Debt = 212.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 172.1m EUR (from shortTermDebt, last quarter)
Debt = 506.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 125.9m EUR (from netDebt column, last quarter)
Enterprise Value = 12.46b EUR (12.34b + Debt 506.4m - CCE 380.5m)
Interest Coverage Ratio = 40.01 (Ebit TTM 1.03b / Interest Expense TTM 25.9m)
FCF Yield = 4.78% (FCF TTM 595.8m / Enterprise Value 12.46b)
FCF Margin = 8.75% (FCF TTM 595.8m / Revenue TTM 6.81b)
Net Margin = 9.70% (Net Income TTM 660.4m / Revenue TTM 6.81b)
Gross Margin = 54.80% ((Revenue TTM 6.81b - Cost of Revenue TTM 3.08b) / Revenue TTM)
Gross Margin QoQ = 57.09% (prev 51.87%)
Tobins Q-Ratio = 2.32 (Enterprise Value 12.46b / Total Assets 5.37b)
Interest Expense / Debt = 1.48% (Interest Expense 7.50m / Debt 506.4m)
Taxrate = 24.67% (52.6m / 213.2m)
NOPAT = 779.2m (EBIT 1.03b * (1 - 24.67%))
Current Ratio = 2.27 (Total Current Assets 2.28b / Total Current Liabilities 1.00b)
Debt / Equity = 0.13 (Debt 506.4m / totalStockholderEquity, last quarter 3.93b)
Debt / EBITDA = 0.08 (Net Debt 125.9m / EBITDA 1.53b)
Debt / FCF = 0.21 (Net Debt 125.9m / FCF TTM 595.8m)
Total Stockholder Equity = 3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.31% (Net Income 660.4m / Total Assets 5.37b)
RoE = 16.76% (Net Income TTM 660.4m / Total Stockholder Equity 3.94b)
RoCE = 24.91% (EBIT 1.03b / Capital Employed (Equity 3.94b + L.T.Debt 212.8m))
RoIC = 18.32% (NOPAT 779.2m / Invested Capital 4.25b)
WACC = 5.91% (E(12.34b)/V(12.84b) * Re(6.11%) + D(506.4m)/V(12.84b) * Rd(1.48%) * (1-Tc(0.25)))
Discount Rate = 6.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.02%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈413.0m ; Y1≈509.5m ; Y5≈869.4m
Fair Price DCF = 125.2 (DCF Value 14.79b / Shares Outstanding 118.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -9.53 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 9.02 | Revenue CAGR: 7.57% | SUE: 1.17 | # QB: 1
EPS next Year (2026-12-31): EPS=4.97 | Chg30d=-0.005 | Revisions Net=-6 | Growth EPS=+8.4% | Growth Revenue=+7.3%